Alnylam Pharmaceuticals | ALNY - Market Capitalization

Stock Price
326.52
Daily Change
-6.33 -1.90%
Monthly
-9.64%
Yearly
33.90%
Q1 Forecast
325.77

Alnylam Pharmaceuticals reported $42.93B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.09B 492M Feb/2026
Agios Pharmaceuticals USD 1.6B 16M Feb/2026
Alnylam Pharmaceuticals USD 39.74B 12.8B Feb/2026
Amgen USD 201.45B 25.2B Feb/2026
Arrowhead Research USD 8.04B 973M Feb/2026
BioCryst Pharmaceuticals USD 1.23B 115M Dec/2023
BioMarin Pharmaceutical USD 11.99B 575M Feb/2026
Incyte USD 22.7B 3.31B Feb/2026
Ionis Pharmaceuticals USD 12.16B 652M Feb/2026
Moderna USD 16.5B 6.41B Feb/2026
Neurocrine Biosciences USD 13.68B 465M Feb/2026
Novartis USD 303.91B 57.84B Feb/2026
PTC Therapeutics USD 5.36B 744M Feb/2026
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sanofi EUR 118.94B 1.6B Feb/2026
Sarepta Therapeutics USD 1.77B 249M Feb/2026
Takeda JPY 7.64T 774.9B Dec/2025
Tectonic Therapeutic USD 294M 77M Sep/2025
Ultragenyx Pharmaceutical USD 1.94B 284M Feb/2026
Vertex Pharmaceuticals USD 120.12B 5.09B Feb/2026
Xencor USD 837M 278M Sep/2025